Impact of Nirsevimab Prophylaxis on Paediatric Respiratory Syncytial Virus (RSV)-Related Hospitalisations During the Initial 2023/24 Season in Luxembourg

• 2024

  Log in to bookmark this resource.

  Log in
• Corinna Ernst; Dritan Bejko; Leo Gaasch; Emilie Hannelas; Isaline Kahn; Charlotte Pierron
PMID: 38275017DOI: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.4.2400033

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This study examines the impact of nirsevimab, a new antibody, on reducing RSV-related hospitalizations in Luxembourg during the 2023/24 season. After its introduction, neonatal coverage reached 84%, leading to fewer hospital admissions for infants under six months compared to 2022. The average age of hospitalized children increased, and their hospital stays were shorter. Most severe cases involved non-immunized children. Nirsevimab's effectiveness aligns with clinical trials showing it reduces RSV severity in infants. The study highlights its potential benefits but notes limitations like short observation time and lack of outpatient data monitoring.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Hospitalization; Infant; Infant, Newborn; Luxembourg; Pediatrics; Respiratory Syncytial Virus Infections; Immunization Programs; Respiratory Syncytial Virus, Human; Antibodies, Monoclonal, Humanized

Institutions: European Centre for Disease Prevention and Control (ECDC); European Centre for Disease Prevention and Control (ECDC); Centre Hospitalier de Luxembourg

---

More like this

Universal Infant Immunisation Against Respiratory Syncytial Virus and European Inequalities: The Pandemics Lesson Has Not Been Learnt 2023 · Hôpital Antoine-Béclère AP-HP, Université Paris-Saclay, American College of Emergency Physicians, Hospital General Universitario Gregorio Marañón, St. Marien Children's Hospital, University Medical Centre Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation, University Hospital of Padova Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date 2024 · University of the Witwatersrand Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---